Altimmune Inc

+0.51 (+4.35%)
Products, Regulatory, Earnings Announcements

Altimmune Announces Significant Reductions In Liver Fat Content And Body Weight In 12-Week Phase 1B Clinical Trial Of Pemvidutide In Subjects With NAFLD

Published: 09/14/2022 11:16 GMT
Altimmune Inc (ALT) - Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-week Phase 1b Clinical Trial of Pemvidutide in Subjects With Nafld.
Altimmune Inc - All 3 Pemvidutide Dosing Groups (1.2 Mg, 1.8 Mg, 2.4 Mg) Achieved Primary Endpoint.
Altimmune Inc - Mean Weight Loss of 4.9% (placebo-adjusted 4.7%) in Subjects Without Diabetes Receiving 1.8 Mg Dose at 12 Weeks of Treatment.
Altimmune Inc - Trial Also Met Its Key Secondary Endpoint in All Pemvidutide Treatment Groups.
Altimmune Inc - Pemvidutide Was Reported to Be Generally Well Tolerated.
Revenue is expected to be $0.87 Million
Adjusted EPS is expected to be -$0.51

Next Quarter Revenue Guidance is expected to be $0.87 Million
Next Quarter EPS Guidance is expected to be -$0.48

More details on our Analysts Page.